BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26935861)

  • 1. Downregulation of epidermal growth factor receptor family receptors and ligands in a mutant K-ras group of patients with colorectal cancer.
    Nagaoka T; Kitaura K; Miyata Y; Kumagai K; Kaneda G; Kanazawa H; Suzuki S; Hamada Y; Suzuki R
    Mol Med Rep; 2016 Apr; 13(4):3514-20. PubMed ID: 26935861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Localization of phosphorylated ErbB1-4 and heregulin in colorectal cancer.
    Mitsui K; Yonezawa M; Tatsuguchi A; Shinji S; Gudis K; Tanaka S; Fujimori S; Sakamoto C
    BMC Cancer; 2014 Nov; 14():863. PubMed ID: 25416285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression profiling of ERBB receptors and ligands in human transitional cell carcinoma of the bladder.
    Amsellem-Ouazana D; Bièche I; Tozlu S; Botto H; Debré B; Lidereau R
    J Urol; 2006 Mar; 175(3 Pt 1):1127-32. PubMed ID: 16469638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of the ERBB Family of Ligands and Receptors in Gastric Cancer.
    Byeon SJ; Lee HS; Kim MA; Lee BL; Kim WH
    Pathobiology; 2017; 84(4):210-217. PubMed ID: 28399526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor mutant with wild-type affinity for both ErbB1 and ErbB3.
    Wingens M; Jacobs-Oomen S; van der Woning SP; Stortelers C; van Zoelen EJ
    Biochemistry; 2006 Apr; 45(14):4703-10. PubMed ID: 16584205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ligand-Independent Epidermal Growth Factor Receptor Overexpression Correlates with Poor Prognosis in Colorectal Cancer.
    Yun S; Kwak Y; Nam SK; Seo AN; Oh HK; Kim DW; Kang SB; Lee HS
    Cancer Res Treat; 2018 Oct; 50(4):1351-1361. PubMed ID: 29361822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trophoblast subtype-specific EGFR/ERBB4 expression correlates with cell cycle progression and hyperplasia in complete hydatidiform moles.
    Fock V; Plessl K; Fuchs R; Dekan S; Milla SK; Haider S; Fiala C; Knöfler M; Pollheimer J
    Hum Reprod; 2015 Apr; 30(4):789-99. PubMed ID: 25740878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.
    Belmont PJ; Jiang P; McKee TD; Xie T; Isaacson J; Baryla NE; Roper J; Sinnamon MJ; Lee NV; Kan JL; Guicherit O; Wouters BG; O'Brien CA; Shields D; Olson P; VanArsdale T; Weinrich SL; Rejto P; Christensen JG; Fantin VR; Hung KE; Martin ES
    Sci Signal; 2014 Nov; 7(351):ra107. PubMed ID: 25389372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer.
    Takahashi N; Yamada Y; Furuta K; Nagashima K; Kubo A; Sasaki Y; Shoji H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Hamaguchi T; Shimada Y
    Cancer Sci; 2015 May; 106(5):604-10. PubMed ID: 25707609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of ErbB1-4 expression in invasive breast cancer with clinicopathological characteristics and prognosis.
    Fujiwara S; Ibusuki M; Yamamoto S; Yamamoto Y; Iwase H
    Breast Cancer; 2014 Jul; 21(4):472-81. PubMed ID: 23100016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amphiregulin and Epiregulin mRNA expression in primary colorectal cancer and corresponding liver metastases.
    Kuramochi H; Nakajima G; Kaneko Y; Nakamura A; Inoue Y; Yamamoto M; Hayashi K
    BMC Cancer; 2012 Mar; 12():88. PubMed ID: 22409860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression, localization, and regulation of the neuregulin receptor ErbB3 in mouse heart.
    Campreciós G; Lorita J; Pardina E; Peinado-Onsurbe J; Soley M; Ramírez I
    J Cell Physiol; 2011 Feb; 226(2):450-5. PubMed ID: 20672328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.
    Jacobs B; De Roock W; Piessevaux H; Van Oirbeek R; Biesmans B; De Schutter J; Fieuws S; Vandesompele J; Peeters M; Van Laethem JL; Humblet Y; Pénault-Llorca F; De Hertogh G; Laurent-Puig P; Van Cutsem E; Tejpar S
    J Clin Oncol; 2009 Oct; 27(30):5068-74. PubMed ID: 19738126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of epidermal growth factor receptor 4 in oral leukoplakia.
    Kobayashi H; Kumagai K; Gotoh A; Eguchi T; Yamada H; Hamada Y; Suzuki S; Suzuki R
    Int J Oral Sci; 2013 Mar; 5(1):14-20. PubMed ID: 23492901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of epidermal growth factor receptors and epidermal growth factor, amphiregulin and neuregulin in bovine uteroplacental tissues during gestation.
    Akbalik ME; Ketani MA
    Placenta; 2013 Dec; 34(12):1232-42. PubMed ID: 24138732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The neuregulin-I/ErbB signaling system in development and disease.
    Britsch S
    Adv Anat Embryol Cell Biol; 2007; 190():1-65. PubMed ID: 17432114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Forkhead Box q1 promotes invasion and metastasis in colorectal cancer by activating the epidermal growth factor receptor pathway.
    Zhang JJ; Cao CX; Wan LL; Zhang W; Liu ZJ; Wang JL; Guo Q; Tang H
    World J Gastroenterol; 2022 May; 28(17):1781-1797. PubMed ID: 35633908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
    Khambata-Ford S; Garrett CR; Meropol NJ; Basik M; Harbison CT; Wu S; Wong TW; Huang X; Takimoto CH; Godwin AK; Tan BR; Krishnamurthi SS; Burris HA; Poplin EA; Hidalgo M; Baselga J; Clark EA; Mauro DJ
    J Clin Oncol; 2007 Aug; 25(22):3230-7. PubMed ID: 17664471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.
    Ross JS; Fakih M; Ali SM; Elvin JA; Schrock AB; Suh J; Vergilio JA; Ramkissoon S; Severson E; Daniel S; Fabrizio D; Frampton G; Sun J; Miller VA; Stephens PJ; Gay LM
    Cancer; 2018 Apr; 124(7):1358-1373. PubMed ID: 29338072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.